Summary
Patients from several immune-mediated diseases experience continued trial-and-error testing of new drugs without adequate selection based on personalized molecular patterns of disease. In consequence, the patients suffer from not having an adequate response to the therapy they...
More information & hyperlinks
Web resources: | https://3tr-imi.eu/ |